Overview

Seventy years old and still a first-line drug — the definitive answer to anyone who thinks peptide therapeutics are new. It is also the clearest example of route determining everything: intravenous vancomycin treats bloodstream infection and cannot treat C. difficile, while oral vancomycin treats C. difficile and cannot treat anything else.

FDA ApprovedFDA-approved for serious Gram-positive infections including MRSA, and orally for Clostridioides difficile infection.

At a glance

Regulatory status	FDA-approved for serious Gram-positive infections including MRSA, and orally for Clostridioides difficile infection.
Drug class	Glycopeptide antibiotic — a heavily modified, glycosylated seven-residue peptide
Route	Intravenous; oral for C. difficile colitis (not absorbed)
Half-life	~4–6 hours with normal renal function
Evidence rating	5/5 Very strong Evidence rating 5 out of 5: Very strong Multiple phase 3 randomized trials plus regulatory approval in a major market.
Studied in	Seven decades of clinical use, numerous randomized trials, and randomized comparisons against fidaxomicin and metronidazole for C. difficile.

How it works

Binds the D-alanyl-D-alanine terminus of peptidoglycan precursors, physically blocking transglycosylation and transpeptidation and halting cell wall synthesis. Resistance arises when organisms substitute D-alanyl-D-lactate, which drops binding affinity a thousandfold.

Evidence base

Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.

Seven decades of use plus modern randomized comparisons in C. difficile.
Dosing guidance has changed substantially — AUC-guided dosing superseded trough-only targets.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

Reliable anti-MRSA activity Strong evidence

Long-standing first-line therapy for serious methicillin-resistant staphylococcal infection.
Oral therapy for C. difficile Strong evidence

Because it is not absorbed, oral vancomycin reaches very high colonic concentrations. Superior to metronidazole in randomized comparison and a guideline-recommended first-line agent.
Broad Gram-positive coverage Strong evidence

Active against streptococci, enterococci and Gram-positive anaerobes.
Inexpensive and universally available Strong evidence

Off-patent and stocked essentially everywhere.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

Nephrotoxicity Serious

Dose- and exposure-related acute kidney injury, markedly increased when combined with piperacillin-tazobactam — one of the most clinically important interactions in hospital medicine.
Requires therapeutic drug monitoring Serious

The therapeutic window is narrow; AUC-guided dosing is now recommended over trough-only monitoring.
Vancomycin infusion reaction Moderate evidence

Histamine-mediated flushing of the upper body from rapid infusion. It is a rate-related reaction, not an allergy, and is prevented by slowing the infusion.
Ototoxicity Moderate evidence

Uncommon but potentially permanent, particularly with aminoglycoside co-administration.
Rising MICs and treatment failure Moderate evidence

Creeping minimum inhibitory concentrations in S. aureus are associated with worse outcomes even within the susceptible range.
Slow bactericidal activity Moderate evidence

Kills more slowly than beta-lactams; not the preferred agent for methicillin-susceptible S. aureus.
DRESS and severe cutaneous reactions Serious

Vancomycin is among the more common causes of DRESS syndrome.

Who should avoid it

Known vancomycin hypersensitivity or prior DRESS
Caution in pre-existing renal impairment
Avoid combining with piperacillin-tazobactam where an alternative exists

If used under medical supervision, monitor

AUC-guided therapeutic drug monitoring (preferred) or trough levels
Serum creatinine at least every 2–3 days
Audiometry with prolonged therapy or aminoglycoside co-use
Infusion rate — at least 1 hour per gram

Interactions

Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.

Piperacillin-tazobactam — substantially increased nephrotoxicity risk
Aminoglycosides — additive nephro- and ototoxicity
Loop diuretics — additive ototoxicity
NSAIDs and contrast media — additive renal risk

Commonly confused with

These mix-ups cause real harm — two products sold under one name, or two molecules whose effects run in opposite directions.

Daptomycin FDA Approved Evidence 5/5

Both treat MRSA, and both are peptides. Vancomycin works in the lung; daptomycin is inactivated by surfactant and must never be used for pneumonia.

Compare side by side

Regulatory & legal status

Prescription antibiotic.

Infographic

Vancomycin — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

antibioticMRSAglycopeptideC. difficileapproved

Related peptides in Antimicrobial & Antibiotic

Terms used on this page

Intravenous Administration (IV): Intravenous administration delivers drug directly into the bloodstream, giving complete bioavailability by definition and making it the reference route against which all others are measured.
Binding Affinity: Binding affinity is the strength of the reversible interaction between a ligand and its target, expressed as the concentration at which half the target is occupied at equilibrium.
Therapeutic Window: The therapeutic window is the range of exposure above the concentration needed for effect and below the one producing unacceptable harm, and its width decides how tightly dosing must be controlled.

This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.